# TFE3

## Overview
TFE3 is a gene that encodes a transcription factor belonging to the basic helix-loop-helix leucine zipper (bHLH-LZ) family, which plays a pivotal role in regulating gene expression. The protein product of TFE3, known as transcription factor binding to IGHM enhancer 3, is involved in various cellular processes, including lysosomal biogenesis, autophagy, and metabolic regulation. It functions by binding to specific DNA sequences and forming dimers or higher-order structures, which are essential for its activity as a transcriptional regulator. TFE3 is also implicated in several pathological conditions, such as Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma, where chromosomal translocations result in oncogenic fusion proteins. Additionally, mutations in TFE3 have been linked to neurocutaneous disorders, highlighting its significance in both normal physiology and disease states (Martina2014The; Argani2002PRCCTFE3; Lehalle2020De).

## Structure
The TFE3 protein is characterized by its basic helix-loop-helix leucine zipper (bHLH-LZ) domain, which is crucial for its function as a transcription factor. This domain facilitates both DNA binding and dimerization, essential for TFE3's role in gene regulation (Beckmann1990TFE3:; Yang2021Structural). The helix-loop-helix (HLH) region forms a four-helix bundle structure with a hydrophobic core, while the leucine zipper region promotes dimer interaction and partner selectivity (Yang2021Structural). The leucine zipper is defined by a heptad repeat of leucine residues, which are necessary for DNA binding and dimerization specificity (Roman1992mTFE3; Beckmann1991The).

TFE3 can form homodimers and potentially higher-order structures such as trimers and tetramers, mediated by the bHLH-LZ domain (Artandi1994The). The protein's ability to form these multimeric structures is crucial for its transcriptional activation capabilities, allowing it to interact with distal DNA elements (Artandi1994The). Post-translational modifications, such as phosphorylation, may influence TFE3's subcellular localization and activity, although specific details are not provided in the context. Splice variants of TFE3 may exist, potentially altering its functional properties (Roman1992mTFE3).

## Function
TFE3 is a transcription factor that plays a significant role in lysosomal biogenesis and autophagy by binding to CLEAR elements in the promoters of lysosomal genes. In healthy human cells, TFE3 is involved in the regulation of lysosomal function and biogenesis, particularly in response to nutrient availability. Under nutrient-rich conditions, TFE3 is retained in the cytosol through phosphorylation by mTORC1 and interaction with 14-3-3 proteins. Upon starvation or lysosomal stress, TFE3 translocates to the nucleus, where it activates genes associated with autophagy and lysosomal biogenesis (Martina2014The).

TFE3 shares regulatory mechanisms with TFEB, another member of the MiTF/TFE family, and both factors respond to nutrient variations by translocating to the nucleus upon mTORC1 inactivation. This translocation is crucial for promoting lysosomal biogenesis and autophagy, which are essential for cellular adaptation to nutrient changes (Martina2014The). TFE3 also interacts with the mTORC1 pathway regulator FLCN, suggesting a feedback loop that influences mTORC1 activity (Martina2014The). In the context of lysosomal storage disorders, TFE3 overexpression has been shown to enhance cellular clearance, indicating its potential therapeutic role (Martina2014The).

## Clinical Significance
Mutations and alterations in the TFE3 gene are implicated in several diseases, primarily involving oncogenic processes. TFE3 is notably associated with Xp11 translocation renal cell carcinoma (RCC), a subtype of kidney cancer characterized by chromosomal translocations involving TFE3. These translocations result in fusion proteins such as PRCC-TFE3, NONO-TFE3, and ASPL-TFE3, which contribute to tumorigenesis by dysregulating transcriptional activity (Argani2002PRCCTFE3; Argani2016TFE3Fusion; Tsuda2007TFE3). 

In alveolar soft part sarcoma (ASPS), the ASPSCR1-TFE3 fusion protein is involved in tumor growth and angiogenesis by increasing lactic acid in the tumor microenvironment (Li2023Emerging). TFE3 alterations are also linked to metabolic disorders, as seen in NONO-TFE3 translocation RCC, where the fusion protein affects metabolic regulation, leading to insulin resistance and circadian rhythm disturbances (Li2023Emerging).

De novo mutations in TFE3 are associated with a neurocutaneous disorder characterized by intellectual disability, pigmentary mosaicism, and lysosomal storage disorder-like features. These mutations, particularly in exons 3 and 4, may lead to a gain-of-function effect, impacting the gene's regulatory roles (Diaz2019TFE3‐associated; Lehalle2020De).

## Interactions
TFE3 is a transcription factor that participates in various protein-protein and protein-DNA interactions. It forms heterodimers with TFEC, another basic helix-loop-helix protein, which inhibits TFE3-dependent transcription activation. This interaction is significant because TFEC lacks the acidic domain necessary for transactivation, thus reducing the transactivation caused by TFE3 when both are present (Zhao1993TFEC).

TFE3 also interacts with the E2F3a transcription factor, forming a functional partnership that is crucial for the activation of the DNA polymerase α p68 promoter. This interaction is dependent on the marked box domain of E2F3a, and the presence of both E2F and E-box binding sites is essential for promoter activity (Giangrande2003Identification).

In terms of nucleic acid interactions, TFE3 binds to specific DNA sequences, such as the ixE3 site of the immunoglobulin heavy-chain enhancer, through its helix-loop-helix and leucine zipper motifs. These motifs are essential for TFE3's dimerization and DNA-binding activity (Beckmann1991The). TFE3 can also activate transcription from distal sites by forming multimeric structures, facilitated by its basic helix-loop-helix-zipper domain (Artandi1994The).


## References


[1. (Beckmann1991The) H Beckmann and T Kadesch. The leucine zipper of tfe3 dictates helix-loop-helix dimerization specificity. Genes &amp; Development, 5(6):1057–1066, June 1991. URL: http://dx.doi.org/10.1101/gad.5.6.1057, doi:10.1101/gad.5.6.1057. This article has 93 citations.](https://doi.org/10.1101/gad.5.6.1057)

[2. (Beckmann1990TFE3:) H Beckmann, L K Su, and T Kadesch. Tfe3: a helix-loop-helix protein that activates transcription through the immunoglobulin enhancer mue3 motif. Genes &amp; Development, 4(2):167–179, February 1990. URL: http://dx.doi.org/10.1101/gad.4.2.167, doi:10.1101/gad.4.2.167. This article has 327 citations.](https://doi.org/10.1101/gad.4.2.167)

[3. (Li2023Emerging) Xingyu Li, Yongming Chen, Siqiao Gong, Huixia Chen, Huafeng Liu, Xiaoyu Li, and Junfeng Hao. Emerging roles of tfe3 in metabolic regulation. Cell Death Discovery, March 2023. URL: http://dx.doi.org/10.1038/s41420-023-01395-0, doi:10.1038/s41420-023-01395-0. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41420-023-01395-0)

[4. (Giangrande2003Identification) Paloma H. Giangrande, Timothy C. Hallstrom, Chainarong Tunyaplin, Kathryn Calame, and Joseph R. Nevins. Identification of e-box factor tfe3 as a functional partner for the e2f3 transcription factor. Molecular and Cellular Biology, 23(11):3707–3720, June 2003. URL: http://dx.doi.org/10.1128/mcb.23.11.3707-3720.2003, doi:10.1128/mcb.23.11.3707-3720.2003. This article has 80 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.23.11.3707-3720.2003)

[5. (Martina2014The) José A. Martina, Heba I. Diab, Li Lishu, Lim Jeong-A, Simona Patange, Nina Raben, and Rosa Puertollano. The nutrient-responsive transcription factor tfe3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris. Science Signaling, January 2014. URL: http://dx.doi.org/10.1126/scisignal.2004754, doi:10.1126/scisignal.2004754. This article has 499 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1126/scisignal.2004754)

[6. (Roman1992mTFE3) Christopher Roman, A. Gregory Matera, Cathleen Cooper, Steven Artandi, Stacy Blain, David C. Ward, and Kathryn Calame. Mtfe3, an x-linked transcriptional activator containing basic helix-loop-helix and zipper domains, utilizes the zipper to stabilize both dna binding and multimerization. Molecular and Cellular Biology, 12(2):817–827, February 1992. URL: http://dx.doi.org/10.1128/mcb.12.2.817-827.1992, doi:10.1128/mcb.12.2.817-827.1992. This article has 1 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.12.2.817-827.1992)

[7. (Argani2002PRCCTFE3) Pedram Argani, Cristina R. Antonescu, Jérôme Couturier, Jean-Christophe Fournet, Raf Sciot, Maria Debiec-Rychter, Brian Hutchinson, Victor E. Reuter, Lilliane Boccon-Gibod, Charles Timmons, Naiel Hafez, and Marc Ladanyi. Prcc-tfe3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(x;1)(p11.2;q21). The American Journal of Surgical Pathology, 26(12):1553–1566, December 2002. URL: http://dx.doi.org/10.1097/00000478-200212000-00003, doi:10.1097/00000478-200212000-00003. This article has 276 citations.](https://doi.org/10.1097/00000478-200212000-00003)

[8. (Lehalle2020De) Daphné Lehalle, Pierre Vabres, Arthur Sorlin, Tatjana Bierhals, Magali Avila, Virginie Carmignac, Martin Chevarin, Erin Torti, Yuichi Abe, Tobias Bartolomaeus, Jill Clayton-Smith, Benjamin Cogné, Ivon Cusco, Laurence Duplomb, Eveline De Bont, Yannis Duffourd, Floor Duijkers, Orly Elpeleg, Aviva Fattal, David Geneviève, Maria J Guillen Sacoto, Anne Guimier, David J Harris, Maja Hempel, Bertrand Isidor, Thibaud Jouan, Paul Kuentz, Eriko Koshimizu, Klaske Lichtenbelt, Valerie Loik Ramey, Miriam Maik, Sakoto Miyakate, Yoshiko Murakami, Laurent Pasquier, Helio Pedro, Laurie Simone, Krista Sondergaard-Schatz, Judith St-Onge, Julien Thevenon, Irene Valenzuela, Rami Abou Jamra, Koen van Gassen, Mieke M van Haelst, Silvana van Koningsbruggen, Edgard Verdura, Christa Whelan Habela, Pia Zacher, Jean-Baptiste Rivière, Christel Thauvin-Robinet, Joerg Betschinger, and Laurence Faivre. De novo mutations in the x-linked tfe3 gene cause intellectual disability with pigmentary mosaicism and storage disorder-like features. Journal of Medical Genetics, 57(12):808–819, May 2020. URL: http://dx.doi.org/10.1136/jmedgenet-2019-106508, doi:10.1136/jmedgenet-2019-106508. This article has 11 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1136/jmedgenet-2019-106508)

[9. (Diaz2019TFE3‐associated) Jullianne Diaz, Seth Berger, and Eyby Leon. Tfe3‐associated neurodevelopmental disorder: a distinct recognizable syndrome. American Journal of Medical Genetics Part A, 182(3):584–590, December 2019. URL: http://dx.doi.org/10.1002/ajmg.a.61437, doi:10.1002/ajmg.a.61437. This article has 10 citations.](https://doi.org/10.1002/ajmg.a.61437)

[10. (Yang2021Structural) Guang Yang, Peifeng Li, Zaizhou Liu, Siqi Wu, Chen Zhuang, Hang Qiao, Li Zheng, Pengfei Fang, Chuanhu Lei, and Jing Wang. Structural basis for the dimerization mechanism of human transcription factor e3. Biochemical and Biophysical Research Communications, 569:41–46, September 2021. URL: http://dx.doi.org/10.1016/j.bbrc.2021.06.091, doi:10.1016/j.bbrc.2021.06.091. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2021.06.091)

[11. (Argani2016TFE3Fusion) Pedram Argani, Minghao Zhong, Victor E. Reuter, John T. Fallon, Jonathan I. Epstein, George J. Netto, and Cristina R. Antonescu. Tfe3-fusion variant analysis defines specific clinicopathologic associations among xp11 translocation cancers. American Journal of Surgical Pathology, 40(6):723–737, June 2016. URL: http://dx.doi.org/10.1097/PAS.0000000000000631, doi:10.1097/pas.0000000000000631. This article has 192 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1097/PAS.0000000000000631)

[12. (Zhao1993TFEC) Guang-Quan Zhao, Qi Zhao, Xin Zhou, Marie-Geneviève Mattei, and Benoit de Crombrugghe. Tfec, a basic helix-loop-helix protein, forms heterodimers with tfe3 and inhibits tfe3-dependent transcription activation. Molecular and Cellular Biology, 13(8):4505–4512, August 1993. URL: http://dx.doi.org/10.1128/mcb.13.8.4505-4512.1993, doi:10.1128/mcb.13.8.4505-4512.1993. This article has 8 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.13.8.4505-4512.1993)

[13. (Artandi1994The) Steven E. Artandi, Cathleen Cooper, Ajay Shrivastava, and Kathryn Calame. The basic helix-loop-helix-zipper domain of tfe3 mediates enhancer-promoter interaction. Molecular and Cellular Biology, 14(12):7704–7716, December 1994. URL: http://dx.doi.org/10.1128/mcb.14.12.7704-7716.1994, doi:10.1128/mcb.14.12.7704-7716.1994. This article has 1 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.14.12.7704-7716.1994)

[14. (Tsuda2007TFE3) Masumi Tsuda, Ian J. Davis, Pedram Argani, Neerav Shukla, Gael G. McGill, Makoto Nagai, Tsuyoshi Saito, Marick Laé, David E. Fisher, and Marc Ladanyi. Tfe3 fusions activate met signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic met inhibition. Cancer Research, 67(3):919–929, February 2007. URL: http://dx.doi.org/10.1158/0008-5472.can-06-2855, doi:10.1158/0008-5472.can-06-2855. This article has 257 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/0008-5472.can-06-2855)